RegeneRx Biopharmaceuticals, Inc. (RGRX)
OTCMKTS · Delayed Price · Currency is USD
0.0007
0.00 (0.00%)
Aug 25, 2026, 9:37 AM EST
RGRX Revenue
RegeneRx Biopharmaceuticals had revenue of $19.19K in the quarter ending March 31, 2023, a decrease of -0.01%. This brings the company's revenue in the last twelve months to $76.76K. In the year 2022, RegeneRx Biopharmaceuticals had annual revenue of $76.76K.
Revenue (ttm)
76.76K
Revenue Growth
-0.00%
P/S Ratio
0.01
Revenue / Employee
25.59K
Employees
3
Market Cap
1.06K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 76.76K | - | - |
| Dec 31, 2021 | 76.76K | - | - |
| Dec 31, 2020 | 76.76K | -1.00 | - |
| Dec 31, 2019 | 76.76K | 7.10K | 10.18% |
| Dec 31, 2018 | 69.67K | 13.02K | 22.97% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| American Oriental Bioengineering | 121.58M |
| Affimed | 6.29M |
| DNAPrint Genomics | 1.93M |
| Trevena | 546.00K |
| Proteonomix | 26.00K |
RegeneRx Biopharmaceuticals News
- 3 years ago - RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations - PRNewsWire
- 3 years ago - RegeneRx Receives Stockholder Approval for Reverse Stock Split - PRNewsWire
- 3 years ago - RegeneRx To Extend Consent Solicitation Vote - PRNewsWire
- 3 years ago - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 - PRNewsWire
- 3 years ago - RegeneRx Issues Letter To Stockholders - PRNewsWire
- 3 years ago - Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy - PRNewsWire
- 3 years ago - Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy - PRNewsWire
- 4 years ago - RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease - PRNewsWire